PDHPS1 peptide

PDHPS1 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

H-IATTTASAATAAAIGATPRAK-OH

H-Ile-Ala-Thr-Thr-Thr-Ala-Ser-Ala-Ala-Thr-Ala-Ala-Ala-Ile-Gly-Ala-Thr-Pro-Arg-Ala-Lys-OH

21

95.1%

C₈₁H₁₄₃N₂₅O₂₈

1915.14

Synthetic

Powder

PDHPS1 (peptide deregulated in hypertrophic scar-1) is an endogenous peptide from skin tissue, whose precursor protein is nuclear mitotic apparatus protein 1 (NUMA1), a protein that plays an essential role in the formation and maintenance of the spindle poles and the alignment and the segregation of chromosomes during mitotic cell division. PDHPS1 binds to protein phosphatase 2 phosphatase activator (PTPA), an essential activator of protein phosphatase 2A (PP2A), increasing phosphorylation of the oncogene Yes-associated protein (YAP), further inactivating YAP and suppressing the expression of its downstream target genes. PDHPS1 inhibits the proliferation of ovarian cancer cells in vitro, induces cell apoptosis in ovarian cancer cells and inhibits ovarian tumour growth in a subcutaneous xenograft mouse model.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Pan et al (2022) Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling. Mol Cancer Ther. 21(7) 1160 PMID: 35545004

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.